News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
771,403 Results
Type
Article (67614)
Company Profile (217)
Press Release (703552)
Multimedia
Podcasts (209)
Webinars (34)
Section
Business (206485)
Career Advice (3444)
Deals (36113)
Drug Delivery (174)
Drug Development (84860)
Employer Resources (194)
FDA (18014)
Job Trends (16300)
News (357864)
Policy (37038)
Tag
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (4)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2989)
Academic (2)
Accelerated approval (56)
Adcomms (39)
Allergies (192)
Alliances (53337)
ALS (234)
Alzheimer's disease (1939)
Antibody-drug conjugate (ADC) (531)
Approvals (18351)
Artificial intelligence (804)
Autoimmune disease (345)
Automation (62)
Bankruptcy (376)
Best Places to Work (12142)
BIOSECURE Act (23)
Biosimilars (247)
Biotechnology (137)
Bladder cancer (206)
Brain cancer (83)
Breast cancer (821)
Cancer (6422)
Cardiovascular disease (543)
Career advice (2950)
Career pathing (52)
CAR-T (377)
CDC (76)
Celiac Disease (3)
Cell therapy (1032)
Cervical cancer (52)
Clinical research (73567)
Collaboration (2299)
Company closure (8)
Compensation (1047)
Complete response letters (105)
COVID-19 (3002)
CRISPR (118)
C-suite (1249)
Cystic fibrosis (163)
Data (8484)
Decentralized trials (3)
Denatured (68)
Depression (190)
Dermatology (95)
Diabetes (651)
Diagnostics (7380)
Digital health (62)
Diversity (11)
Diversity, equity & inclusion (47)
Drug discovery (383)
Drug pricing (244)
Drug shortages (38)
Duchenne muscular dystrophy (312)
Earnings (87136)
Editorial (78)
Employer branding (23)
Employer resources (168)
Events (113906)
Executive appointments (1170)
FDA (22002)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1878)
Gene editing (259)
Generative AI (78)
Gene therapy (833)
GLP-1 (1235)
Government (5366)
Grass and pollen (8)
Guidances (418)
Healthcare (20065)
HIV (90)
Huntington's disease (60)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (113)
Immunology and inflammation (346)
Immuno-oncology (112)
Indications (200)
Infectious disease (3393)
Inflammatory bowel disease (238)
Inflation Reduction Act (17)
Influenza (148)
Intellectual property (309)
Interviews (667)
IPO (16495)
IRA (60)
Job creations (4452)
Job search strategy (2390)
JPM (73)
Kidney cancer (22)
Labor market (112)
Layoffs (676)
Leadership (53)
Legal (9350)
Liver cancer (110)
Longevity (35)
Lung cancer (861)
Lymphoma (459)
Machine learning (65)
Management (64)
Manufacturing (1180)
MASH (218)
Medical device (14367)
Medtech (14506)
Mergers & acquisitions (20873)
Metabolic disorders (1723)
mRNA (254)
Multiple sclerosis (202)
NASH (24)
Neurodegenerative disease (491)
Neuropsychiatric disorders (125)
Neuroscience (3640)
Neurotech (1)
NextGen: Class of 2026 (7147)
Non-profit (5057)
Now hiring (64)
Obesity (825)
Opinion (370)
Ovarian cancer (238)
Pain (280)
Pancreatic cancer (340)
Parkinson's disease (408)
Partnered (37)
Patents (635)
Patient recruitment (727)
Peanut (69)
People (61079)
Pharmaceutical (49)
Pharmacy benefit managers (36)
Phase 1 (22640)
Phase 2 (32086)
Phase 3 (24528)
Pipeline (9523)
Policy (388)
Postmarket research (2931)
Preclinical (9810)
Press Release (71)
Prostate cancer (339)
Psychedelics (68)
Radiopharmaceuticals (352)
Rare diseases (1227)
Real estate (6604)
Recruiting (79)
Regulatory (28302)
Reports (63)
Research institute (2728)
Resumes & cover letters (533)
Rett syndrome (40)
RNA editing (27)
RSV (98)
Schizophrenia (194)
Series A (319)
Series B (227)
Service/supplier (9)
Sickle cell disease (125)
Special edition (32)
Spinal muscular atrophy (185)
Sponsored (55)
Startups (3916)
State (2)
Stomach cancer (21)
Supply chain (141)
Tariffs (104)
The Weekly (138)
Vaccines (1276)
Venture capital (127)
Weight loss (564)
Women's health (135)
Worklife (24)
Date
Last 7 days (742)
Last 30 days (3081)
Last 365 days (31282)
2026 (14873)
2025 (31230)
2024 (35695)
2023 (40295)
2022 (51389)
2021 (56010)
2020 (55314)
2019 (49215)
2018 (37482)
2017 (34934)
2016 (34626)
2015 (39811)
2014 (33839)
2013 (30171)
2012 (30838)
2011 (31115)
2010 (29549)
Location
Africa (1093)
Alabama (100)
Alaska (7)
Arizona (332)
Arkansas (16)
Asia (46872)
Australia (7985)
California (13276)
Canada (3885)
China (1527)
Colorado (591)
Connecticut (602)
Delaware (401)
Europe (106275)
Florida (2080)
Georgia (450)
Hawaii (3)
Idaho (66)
Illinois (1166)
India (100)
Indiana (630)
Iowa (23)
Japan (578)
Kansas (136)
Kentucky (54)
Louisiana (48)
Maine (89)
Maryland (1635)
Massachusetts (9530)
Michigan (407)
Minnesota (708)
Mississippi (7)
Missouri (160)
Montana (37)
Nebraska (30)
Nevada (152)
New Hampshire (92)
New Jersey (3672)
New Mexico (33)
New York (3566)
North Carolina (1754)
North Dakota (11)
Northern California (6615)
Ohio (424)
Oklahoma (24)
Oregon (45)
Pennsylvania (2684)
Puerto Rico (30)
Rhode Island (51)
South America (1465)
South Carolina (88)
South Dakota (1)
Southern California (5266)
Tennessee (216)
Texas (2180)
United States (47848)
Utah (422)
Vermont (1)
Virginia (345)
Washington D.C. (85)
Washington State (1088)
West Virginia (4)
Wisconsin (134)
Wyoming (2)
771,403 Results for "la jolla institute for allergy and immunology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS
April 30, 2026
·
1 min read
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases.
April 18, 2024
·
2 min read
Press Releases
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
May 27, 2026
·
7 min read
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions.
May 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
February 10, 2026
·
25 min read
Press Releases
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards
May 27, 2026
·
6 min read
Press Releases
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 12, 2026
·
4 min read
Press Releases
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026
·
10 min read
Venture capital
After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar
Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.
March 3, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 11, 2026
·
8 min read
1 of 77,141
Next
